Competitive vs Non-Competitive Antagonism

A competitive antagonist binds reversibly at the orthosteric site and simply gets in the way. Raising the agonist concentration restores the full response, so the concentration-response curve shifts to the right in parallel with its maximum intact. Non-competitive antagonism covers everything that cannot be outrun: binding to a separate site that prevents activation, blocking the channel or the transducer downstream, or binding the orthosteric site irreversibly. The signature is a depressed maximum rather than a shift.

The distinction shows up wherever an antidote is needed. Naloxone competes with opioids at the mu receptor, which is why a large enough opioid burden can overwhelm a given dose and why its effect can outlast or underlast the agonist. Ketamine blocks the open NMDA receptor channel and cannot be displaced by more glutamate. Aspirin acetylates cyclo-oxygenase covalently, so the block persists until new enzyme is made, which in platelets means new platelets. Degarelix, a GnRH receptor antagonist, competes at the same site the hormone uses and suppresses gonadotropins immediately, without the initial surge a GnRH agonist causes.

The practical question the distinction answers is whether more agonist fixes the problem. If it does, dose and timing govern the outcome and the block ends when the antagonist clears. If it does not, recovery depends on protein turnover, and the ceiling on response is a fixed property of the exposure rather than something titration can escape.

The frequent error is inferring mechanism from the curve alone. Under non-equilibrium conditions, or in a tissue with little receptor reserve, a genuinely competitive antagonist can depress the maximum and look insurmountable. The reverse also happens: allosteric modulators get labelled non-competitive and then treated as though they were irreversible, which they are not.